Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions

Abstract

Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.